文献速递外周动脉疾病

药物涂层球囊股腘动脉血运重建后医疗资源利用:全国队列分析

Health Care Utilization Following Inpatient Femoropopliteal Revascularization With Drug-Coated Balloon Angioplasty: A Nationwide Cohort Analysis.
PubMed 文献 · J Endovasc Ther · 2021-01-11

DCB组合并症更重,但6个月再入院率降低(OR 0.90,95%CI 0.83-0.98,p=0.014),住院更短、费用更低、截肢更少。

要点

  • DCB组患者合并慢性肢体威胁性缺血、糖尿病等更重,但住院更短、费用更低。
  • 普通球囊组再入院更多因早期手术相关并发症(17.5% vs 13.3%)。

核心结论

  • 股腘动脉腔内治疗中DCB使用少于普通球囊,但DCB与6个月内再入院率降低相关。

研究设计与样本

  • 回顾性全国队列分析,纳入2016-2017年全国再入院数据库中24022例股腘动脉血运重建后存活出院患者,DCB组7850例,普通球囊组16172例。

主要发现

  • DCB组慢性肢体威胁性缺血、糖尿病、高血压和吸烟比例更高。
  • DCB组住院时间更短、中位住院费用更低、住院期间下肢截肢更少。
  • 6个月再入院率DCB组低于普通球囊组(OR 0.90,95%CI 0.83-0.98,p=0.014)。
  • 再入院最常见原因为手术相关并发症(15.4%)和糖尿病(15.4%)。
  • 普通球囊组再入院因早期手术相关并发症更常见(17.5% vs 13.3%)。

临床怎么用

  • 对于股腘动脉闭塞性疾病,DCB虽常用于合并症更重的患者,但仍与6个月内再入院减少相关。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To examine nationwide variations in inpatient use of drug-coated balloons (DCBs) for treating femoropopliteal segment occlusive disease and whether DCBs are associated with reduced early out-of-hospital health care utilization. MATERIALS AND METHODS: The study included 24,022 patients who survived hospitalization for femoropopliteal revascularization using DCB angioplasty (n=7850) or uncoated balloon angioplasty (n=16,172) in the 2016-2017 Nationwide Readmissions Database. Differences in patient, hospitalization, and institutional characteristics were compared between treatment strategies. Adjusted logistic regression models were used to examine differences in 6-month rates of readmission, amputation, and repeat intervention. Results are presented as the odds ratio (OR) and 95% confidence interval (CI). RESULTS: Patients treated with DCBs had a higher prevalence of chronic limb-threatening ischemia, diabetes, hypertension, and tobacco use. Revascularization with a DCB was associated with shorter hospitalizations, lower median hospitalization costs, and fewer inpatient lower extremity amputations. Readmissions at 6 months were decreased in patients treated with DCBs compared with uncoated balloon angioplasty (OR 0.90, 95% CI 0.83 to 0.98, p=0.014). The most common reasons for readmission were complications related to procedures (15.4%) and diabetes (15.4%). Compared to patients treated with DCBs, patients treated with uncoated balloon angioplasty were more often readmitted with early procedure-related complications (13.3% vs 17.5%). There were no between-group differences in readmission for sepsis, myocardial infarction, or congestive heart failure. CONCLUSION: DCBs are less often used compared to uncoated balloons during inpatient femoropopliteal procedures. While DCB utilization is associated with more severe comorbidities and advanced peripheral artery disease, readmission rates are decreased through the first 6 months.

来源:J Endovasc Ther,查看原文。版权归原作者所有。

引用

  1. Gurin MI, Beyer SE, Weinberg M, et al. Health Care Utilization Following Inpatient Femoropopliteal Revascularization With Drug-Coated Balloon Angioplasty: A Nationwide Cohort Analysis. J Endovasc Ther. 2021. PMID: 33426984. doi:10.1177/1526602820984111

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。